|
For Severe Asthma, Most Surveyed U.S. Payers Would Reimburse a Novel …
MarketWatch Efficacy versus price: Results of a conjoint analysis indicate that in severe asthma, U.S. pulmonologists are willing to prescribe a novel therapy with strong efficacy in reductions in exacerbations and oral corticosteroid dose even if that drug … |
View full post on asthma – Google News